HTA Methodology Shifts & AI Integration

MarcusWelcome to the Access Brief — your daily briefing on what's moving in HEOR, HTA, and market access. I'm Marcus, and it's great to have you with us today.

SaraAnd I'm Sara. Always good to be here — and I'll say, today's topics feel particularly timely given the rapid pace of methodological innovation.

MarcusSame here. We're looking at NICE's threshold consultation implications — which could redefine cost-effectiveness boundaries. Then EMA's adaptive licensing expansion for rare diseases — potentially accelerating access for underserved populations. And CMS Part D redesign operational hurdles — highlighting real-world implementation challenges.

SaraThat second one about adaptive licensing is especially intriguing — the budget impact question there is one the field hasn't fully worked out yet, particularly for ultra-orphan therapies.

MarcusExactly. Let's get into it.

MarcusStarting with NICE's threshold consultation. The implications are significant — we're seeing a potential shift from the £20k-30k per QALY range toward £50k for highly specialized technologies. This could open doors for gene therapies but also create new access challenges for established treatments.

SaraThat's one read — I'd frame it slightly differently. The real question is whether this signals a permanent threshold elevation or a temporary adjustment for specific disease areas. What strikes me is the lack of clarity on how this interacts with NICE's equity weighting.

MarcusFair point. And what's interesting here is how this consultation coincides with the EU's Critical Medicines Act timeline acceleration. There's a global conversation emerging about how to value transformative therapies.

SaraThe part that gives me pause is the operational implications. If thresholds rise, how does that interact with NICE's prioritization framework? We might see more technologies entering the system but facing longer appraisal times due to capacity constraints.

MarcusThat connects to something I keep coming back to — the tension between innovation incentives and system sustainability. Higher thresholds could incentivize R&D but also strain budgets. I wonder if that's the full picture though... we haven't seen how NHS England will fund the consequential cost increases.

SaraThat's fair, though I think payers would see it differently. The bigger concern is opportunity cost — every pound spent on a £50k/QALY drug is a pound not spent on other treatments. The consultation doesn't address how to manage that trade-off at system level.

MarcusExactly. And from the payer side, the lack of transition procedures for existing technologies creates uncertainty. This is one of those stories where the intent is clear but the execution details will determine real-world impact.

SaraShifting to EMA's adaptive licensing expansion for rare diseases. This builds on their existing adaptive pathways but specifically targets ultra-orphan conditions with high unmet need. The key innovation is allowing earlier conditional approvals based on smaller datasets.

MarcusThat's a significant development — potentially reducing development timelines by 2-3 years for some rare disease therapies. What strikes me is how this could reshape HEOR evidence generation. We'll need real-world data much earlier in the lifecycle to confirm post-approval benefits.

SaraThe part that gives me pause is the risk-benefit balance. Accelerated approvals based on surrogate endpoints have historically faced challenges in confirmatory trials. How will EMA ensure these expansions don't compromise safety standards?

MarcusThat's a valid concern. And what's interesting is how this connects to FDA's decentralized trials guidance. Both agencies are trying to generate evidence more efficiently but with different risk tolerances. EMA's approach seems more structured than FDA's breakthrough pathway.

SaraExactly. And from the payer side, the budget impact implications are substantial. If more rare disease drugs reach market faster, we'll need new approaches to managed entry agreements. The current EMA-NICE aligned pathway isn't designed for this pace.

MarcusThat connects to something I keep coming back to — the need for global evidence standards. If EMA and FDA diverge on evidence requirements, companies will face duplicative development costs. I'd push back slightly on that... actually, the harmonization efforts through HTAi might help here.

SaraThe bigger picture is about patient access. This expansion could benefit patients with ultra-rare conditions who currently have no treatment options. But we need robust pharmacovigilance systems to monitor outcomes post-approval.

MarcusExactly. This is one of those stories where the potential benefits are clear, but the long-term system impact remains to be seen.

MarcusNow CMS Part D redesign operational hurdles. The implementation is facing significant challenges, particularly with the inflation rebates and coverage gap modifications. The operational complexity is creating uncertainty for manufacturers and PBMs alike.

SaraThat's one read — I'd frame it slightly differently. The real issue is the lack of clarity on how the new coverage gap will interact with manufacturer discount programs. What strikes me is the potential for unintended consequences in the insulin market.

MarcusFair point. And what's interesting here is how this redesign coincides with the FTC-CVS settlement over insulin pricing. There's a tension between policy goals and market realities.

SaraThe part that gives me pause is the administrative burden. Small manufacturers may struggle to comply with the new reporting requirements, potentially consolidating the market further. That's the opposite of competition goals.

MarcusThat connects to something I keep coming back to — the IRA's impact on HEOR evidence generation. With price negotiations looming, companies need more robust evidence to support value. But the operational hurdles are diverting resources from evidence generation to compliance.

SaraExactly. And from the payer side, the redesign creates new access challenges for biologics. The coverage gap modifications aren't aligned with formulary management practices, leading to potential patient cost increases.

MarcusI wonder if that's the full picture though... CMS hasn't addressed how the new system will impact Medicaid dual eligibles. That population often faces the highest barriers to access.

SaraThat's fair, though I think payers would see it differently. The bigger concern is the timing. With implementation accelerating, there's no runway for adjustments if early data shows unintended consequences.

MarcusExactly. This is one of those stories where the policy intent is sound but the execution details will determine whether it improves or hinders access.

SaraFinally, FDA's decentralized trials guidance impact. The draft guidance emphasizes virtual components and site flexibility, particularly for rare diseases and neurodegenerative conditions. This could significantly expand patient access to trials.

MarcusThat's a game-changer — potentially reducing trial recruitment timelines by 30-40% for some indications. What strikes me is how this intersects with real-world evidence generation. Decentralized trials could provide more representative data than traditional site-based approaches.

SaraThe part that gives me pause is data quality concerns. How will FDA ensure consistent endpoints and data collection across diverse settings? Remote monitoring isn't foolproof.

MarcusThat's a valid concern. And what's interesting is how this connects to EMA's adaptive licensing expansion. Both agencies are trying to generate evidence more efficiently but with different approaches to risk assessment.

SaraExactly. And from the payer side, the implications for HTA submissions are significant. If trials become more decentralized, we'll need new methods for evaluating external validity. The current HTA frameworks aren't designed for this evidence landscape.

MarcusThat connects to something I keep coming back to — the need for international evidence standards. If FDA and EMA diverge on trial design requirements, companies will face duplicative development costs. I'd push back slightly on that... actually, the ICH E8(R1) guidelines might help harmonize approaches.

SaraThe bigger picture is about patient diversity. Decentralized trials can include traditionally underrepresented populations, which could improve the generalizability of results. But we need robust methodologies to analyze this data.

MarcusExactly. This is one of those stories where the potential benefits are clear, but the methodological challenges are substantial. The next 12 months will be critical in defining how decentralized trials shape future evidence generation.

SaraA lot to think about today. I'll be watching how NICE's threshold consultation interacts with the EU Critical Medicines Act implementation. The global alignment on value thresholds could be transformative.

MarcusSame — and for me the thread running through today is the tension between innovation acceleration and evidence robustness. Every development aims to speed up access, but we need to ensure the evidence foundation remains sound.

SaraThanks so much for listening — really glad you're here with us.

MarcusWe'll be back tomorrow. Show notes and transcripts at outcomes-analytica.no. See you then.

SaraThanks for listening — see you tomorrow.

MarcusBack tomorrow on Access Brief. Show notes at outcomes-analytica.no.